---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-24-000040"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:30:45.273907+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allogene expands CD19 rights to EU/UK; Q1 net loss $65M; cash $397M into 2026

## Summary
- Expanded CD19 oncology rights to all EU Member States and UK from Servier; combined market opportunity increased to >$9.5B from $6B.
- Q1 2024 net loss of $65.0M ($0.38 per share); R&D expenses $52.3M, G&A $17.3M.
- Cash, cash equivalents, and investments $397.3M as of March 31, 2024; cash runway expected into 2026.
- Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL to start mid-2024; primary EFS data readout expected 2H 2026.
- Initial data from Phase 1 cema-cel CLL trial expected by YE 2024; ALLO-329 IND planned Q1 2025.

## SEC filing metadata
- accession: 0001737287-24-000040
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/0001737287-24-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/allo-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-24-000040
- JSON: https://secwatch.observer/filing/0001737287-24-000040.json
- Plain text: https://secwatch.observer/filing/0001737287-24-000040.txt

## Key facts
- Earnings Releases
  Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/0001737287-24-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.